Predictors of sustained functional cure in hepatitis B envelope antigen‐negative patients achieving hepatitis B surface antigen seroclearance with interferon‐alpha

Predictors of sustained functional cure in hepatitis B envelope antigen‐negative patients achieving hepatitis B surface antigen seroclearance with interferon‐alpha–based therapy

Published:2019-07 Issue:S1 Volume:26 Page:32-41
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Li Ming‐Hui¹,Yi Wei²,Zhang Lu¹,Lu Yao¹,Lu Hui‐Hui¹,Shen Ge¹,Wu Shu‐Ling¹,Hao Hong‐Xiao¹,Gao Yuan‐Jiao¹,Chang Min¹,Liu Ru‐Yu¹,Hu Lei‐Ping¹,Cao Wei‐Hua¹,Chen Qi‐Qi¹,Li Jun‐Nan³,Wan Gang⁴,Xie Yao¹

Affiliation:

1. Department of Hepatology Division 2 Beijing Ditan Hospital Capital Medical University Beijing China

2. Department of Gynecology and Obstetrics Beijing Ditan Hospital Capital Medical University Beijing China

3. Scientific Research and Education Department Beijing Ditan Hospital Capital Medical University Beijing China

4. Medical Records and Statistics Department Beijing Ditan Hospital Capital Medical University Beijing China

Funder

Beijing Municipal Science & Technology Commission

Beijing Municipal Administration of Hospitals Clinical Medicine Development for special funding support

National Science and Technology Major Project of China

Beijing Science and Technology Commission

Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13151

Reference46 articles.

1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection;European Association for the Study of the Liver;J Hepatol,2017

2. AASLD guidelines for treatment of chronic hepatitis B;Terrault NA;Hepatology,2016

3. Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update;Sarin SK;Hepatol Int,2016

4. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg‐positive chronic hepatitis B: a five‐year observational cohort study;Li SY;J Viral Hepat,2017

5. Interferon‐based treatment is superior to nucleos(t)ide analog in reducing HBV‐related hepatocellular carcinoma for chronic hepatitis B patients at high risk;Ren P;Expert Opin Biol Ther,2018

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management;World Journal of Hepatology;2024-04-27

2. Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function;Virology Journal;2024-03-30

3. Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysis;Hepatology International;2024-03-09

4. Comparison of the Clinical Curative Efficacy of Interferon Monotherapy and Combined with Nucleotide Analogues in the Treatment-Naive Patients with Chronic Hepatitis B;Advances in Clinical Medicine;2024

5. Research Progress of Pegylated Interferon Therapy for Chronic HBV Infection;Advances in Clinical Medicine;2024